The Recall Desk
HighFDA (Drugs)·D-0301-2026·Announced 2026-02-11

[pending] BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE (BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE)

Pending LLM rewrite. Source: FDA_DRUG D-0301-2026.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: Pending LLM scoring against the rubric.

Plain-English summary

cGMP Deviations: recall due to not meeting the N-Nitroso Bisoprolol impurity specification limits.

The recalled product

Product
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE (BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE)
Brand
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE
Manufacturer
Unichem Pharmaceuticals USA Inc.

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot # GBHL24005A
  • Exp Date: 09/2026

Distribution

Distributed nationwide across the United States.

Same brand · BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE